Skip to main content
. 2016 Sep 2;12(9):e1005875. doi: 10.1371/journal.ppat.1005875

Fig 11. Mice infected with SeV after treatment with Dexa + Cy are protected from a secondary lethal challenge.

Fig 11

(A) Serum SeV-specific IgG levels measured 1 day before challenge. The data are representative of 2 independent experiments with 3 mice per group. (B–D) Bioluminescence in the nasopharynx (B), trachea (C), and lungs (D) after challenge with SeV. The data are averages of 2 independent experiments with 8 mice per group. Error bars represent standard deviation. Statistics: 2-Way ANOVA; ***P < 0.001.